Semaglutide for Weight Loss
The most widely prescribed GLP-1 medication for weight loss and type 2 diabetes management.
Reviewed by GlobalGLP1 editorial team • Drug facts last checked August 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Jump to a section
Overview
Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus. It works by copying a natural hunger hormone called GLP-1, which tells your brain you are full and slows digestion. Novo Nordisk originally developed it for type 2 diabetes (Ozempic, 2017), then got it approved at a higher dose for weight loss (Wegovy, 2021). In December 2025 the FDA approved a daily semaglutide tablet for weight loss, sold as the Wegovy pill, and in March 2026 an even higher injectable dose called Wegovy HD was approved. Semaglutide is the most widely prescribed GLP-1 medication in the world, with clinical trials showing 15 to 17% average body weight loss.
How Semaglutide Works
Semaglutide copies a hormone your body already makes called GLP-1. This hormone does three things: it tells your brain you are full (so you eat less without fighting hunger), it slows down how fast food leaves your stomach (so you stay satisfied longer), and it helps the pancreas release insulin after meals (which controls blood sugar). You take it as a once-weekly shot, or as a daily tablet (the Wegovy pill for weight loss, Rybelsus for diabetes). Most people notice reduced appetite within the first week or two.
FDA Approval
Ozempic
Type 2 diabetes mellitus
0.25 mg, 0.5 mg, 1 mg, 2 mg weekly injection
Rybelsus
Type 2 diabetes mellitus
3 mg, 7 mg, 14 mg daily oral tablet
Wegovy
Chronic weight management
0.25 mg to 2.4 mg weekly injection (escalating dose)
Wegovy
Reducing heart attack and stroke risk in adults with cardiovascular disease and obesity
2.4 mg weekly injection
Ozempic
Slowing chronic kidney disease in adults with type 2 diabetes
Existing weekly doses
Wegovy
Noncirrhotic MASH with moderate to advanced liver fibrosis (accelerated approval)
2.4 mg weekly injection
Wegovy pill
Chronic weight management (oral)
1.5 mg, 4 mg, 9 mg, 25 mg daily tablet
Wegovy HD
Chronic weight management (higher dose)
7.2 mg weekly injection
How You Take It
You start at a low dose and work your way up over several months. The slow build-up is important because it gives your body time to adjust and reduces stomach side effects. Most weight loss happens once you reach the full dose.
How Much Weight You Can Lose
In the main weight loss trial, people on Wegovy 2.4 mg lost about 14.9% of their body weight over 68 weeks (about 16 months). That is the figure counting everyone who started, including people who stopped early. The other figure you will see, 16.9%, is estimated assuming everyone stayed on treatment. Trials report both numbers, and knowing which one you are looking at matters when you compare two drugs. About one in three lost 20% or more. For a 200-pound person, 15% is roughly 30 pounds. Results vary from person to person depending on dose, diet, exercise, and how your body responds.
Blood sugar effect: 1.0 to 1.8 points (Ozempic, for diabetes)
Side Effects
Common Side Effects
- Nausea (about 44% of users in the STEP 1 trial; usually worst during dose increases and eases after a few weeks)
- Diarrhea (about 32% of users; usually mild and short-lived)
- Vomiting (about 25% of users; tends to drop off after the first month or two)
- Constipation (about 23% of users; staying hydrated and adding fiber usually helps)
- Abdominal pain (about 20% of users; usually mild)
- Headache (about 14% of users)
- Fatigue (about 11% of users; often improves as your body adjusts)
- Injection site reactions (uncommon; mild redness or itching near the shot)
Rare but Serious
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning, observed in rodents)
- Hypoglycemia (when combined with insulin or sulfonylureas)
- Kidney injury (due to dehydration from GI effects)
- Allergic reactions
- Breathing food or liquid into the lungs during surgery under general anesthesia or deep sedation. These drugs slow the stomach down, so tell your surgeon, anesthetist and dentist that you take one before any planned procedure
- Worsening of diabetic eye disease in people with type 2 diabetes who already have retinopathy. The label asks for monitoring; this is not described as a risk for people without diabetes
Managing side effects: Most stomach-related side effects show up during the first few weeks and during dose increases, then ease as your body adjusts. The slow dose build-up exists for this reason. Eating smaller meals, staying hydrated, and avoiding fatty or fried foods help a lot. If nausea is bad enough that you cannot keep food down, contact your provider. They can slow the dose escalation or pause it for a cycle.
Semaglutide Cost & Savings (2026)
Savings programs: Novo Nordisk offers savings cards for eligible commercially insured patients. NovoCare patient assistance program available for uninsured/underinsured patients.
Who Should Not Take Semaglutide
- Personal or family history of a type of thyroid cancer called medullary thyroid carcinoma (MTC)
- A rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Allergy to semaglutide or any ingredient in the medication
- Pregnancy or planning to become pregnant (stop at least 2 months before conception)
- History of inflamed pancreas (pancreatitis) — use with caution
Heart Health
The SELECT trial followed over 17,600 adults with obesity and heart disease (but not diabetes) for about 3 years. People on semaglutide 2.4 mg had 20% fewer major heart events compared to placebo. This led the FDA to expand Wegovy's label to include reducing cardiovascular risk.
What this means for you: Semaglutide is the first GLP-1 medication with proven heart benefits in people who do not have diabetes. If you have both obesity and heart disease, this is a major reason doctors and insurance plans favor semaglutide.
What to Expect, Month by Month
Most patients notice decreased hunger and food cravings. Portion sizes naturally decrease.
Measurable weight loss begins as doses escalate. Average 2-4% body weight lost during escalation phase.
Maintenance dose reached. Consistent weight loss of 1-2 lbs per week. Most GI side effects have resolved.
Average 10-15% body weight lost. Blood pressure, cholesterol, and blood sugar improvements measurable.
Weight loss plateau at 15-17% average. Metabolic health markers stabilized. Maintenance phase begins.
Other Medications to Watch
Can cause dangerously low blood sugar when combined. Your doctor will likely reduce your insulin dose by 20 to 50% when starting semaglutide.
Because semaglutide slows digestion, pills you take by mouth may absorb differently. Take other oral medications at least 1 hour before your semaglutide injection day meals.
Slower digestion can change how warfarin absorbs. Your doctor should check your clotting levels (INR) more often when starting or changing your semaglutide dose.
Unlike tirzepatide and orforglipron, the Wegovy and Ozempic labels carry no warning about birth control pills and ask for no change. Semaglutide does slow digestion, so if you want extra reassurance in the first few weeks you can add a barrier method, but the label does not require it. Semaglutide may cause fetal harm, so use reliable contraception either way.
Special Situations
Do not use during pregnancy. Stop semaglutide at least 2 months before trying to conceive because it stays in your system for weeks. Animal studies showed harm to the fetus.
No dose change needed for mild or moderate kidney issues. If you have severe kidney disease, use with caution because the nausea and vomiting can cause dehydration, which makes kidney problems worse.
No dose change needed. Semaglutide levels were the same in people with mild, moderate and severe liver impairment, which is why the label sets no adjustment.
No dose change needed. The Wegovy trials included 233 people aged 65 to 74 and 23 aged 75 or older. Older adults should watch for dehydration, since stomach side effects can cause extra fluid loss.
Wegovy is FDA-approved for teens 12 and older with obesity. In the STEP TEENS trial, adolescents saw a 16.1% reduction in BMI. The dosing schedule is the same as for adults.
What Happens If You Stop
In the STEP 1 follow-up, people who stopped semaglutide after 68 weeks regained about two-thirds of the weight they had lost over the following year. Improvements in blood sugar, blood pressure, and cholesterol also partially reversed.
How to make stopping easier: Tapering your dose gradually (instead of stopping suddenly), building exercise habits while on the medication, working with a dietitian, and transitioning to a lower-cost maintenance plan can all reduce regain. Some doctors recommend staying on a low maintenance dose long-term.
Semaglutide FAQs
Both contain semaglutide but at different doses and for different FDA-approved uses. Ozempic (max 2 mg/week) is approved for type 2 diabetes. Wegovy (max 2.4 mg/week) is approved for weight management. The higher Wegovy dose produces greater weight loss.
Most people notice reduced appetite within 1-2 weeks. Significant weight loss typically begins after reaching the maintenance dose (8-20 weeks, depending on the formulation). Full weight loss effects are usually seen over 12-18 months.
Yes. Wegovy is FDA-approved specifically for weight management in adults with BMI 30+ or BMI 27+ with at least one weight-related condition, regardless of diabetes status.
Studies show that most people regain some weight after stopping semaglutide, typically about two-thirds of the weight lost within one year. This is why many providers recommend long-term use and emphasize building sustainable diet and exercise habits while on the medication.
Compounded semaglutide is not FDA-approved and quality varies between pharmacies. The FDA has issued warnings about some compounded semaglutide products. If choosing compounded, ensure the pharmacy is 503B-registered and your provider monitors your treatment.
Moderate alcohol consumption is generally acceptable, but alcohol can worsen nausea and GI side effects. It also adds empty calories that may slow weight loss. If you have diabetes, alcohol can affect blood sugar levels unpredictably.
Yes. The FDA approved a daily semaglutide tablet for weight management on December 22, 2025, and it reached US pharmacies on January 5, 2026. It is sold as the Wegovy pill and comes in 1.5 mg, 4 mg, 9 mg and 25 mg strengths. In the OASIS 4 trial, people taking it lost about 14% of their body weight over 64 weeks, close to what the weekly Wegovy shot produces. Do not confuse it with Rybelsus, which is the older semaglutide tablet approved for type 2 diabetes at much lower doses.
Wegovy HD is a higher-dose formulation of semaglutide approved by the FDA in March 2026. It allows dose escalation up to 7.2 mg weekly for patients who may benefit from additional weight loss beyond the standard 2.4 mg. In the STEP UP trial, people on the 7.2 mg dose lost an average of 18.7% of their body weight over 72 weeks, counting everyone who started. Novo Nordisk also reports 20.7%, its estimate if everyone had kept taking the drug. Your provider can determine if the higher dose is appropriate for you.
Find Clinics Offering Semaglutide
Compare Semaglutide providers by pricing, telehealth availability, and patient ratings.
Search Semaglutide Clinics →Related Semaglutide resources
Find Semaglutide Clinics by State
Ready to start Semaglutide?
Search our directory of 3,318 GLP-1 clinics. Filter by medication, insurance, and telehealth availability.
References
Every figure on this page comes from one of the following. Prescribing information is linked on DailyMed, which serves the current label rather than a snapshot of an old one. Trials are linked by DOI.
- Wegovy (semaglutide) injection and tablets: prescribing information
- Ozempic (semaglutide) injection: prescribing information
- Rybelsus (oral semaglutide) tablets: prescribing information
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) The 68-week weight-loss trial behind the ~15% figure.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) 17,604 adults; the basis of the heart-risk claim and the 2024 FDA indication.
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4) The 64-week trial behind the Wegovy pill figures.
Drug facts on this page last checked against these sources August 2026.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.